CN110960502A - Substance for treating metabolic syndrome and application thereof - Google Patents
Substance for treating metabolic syndrome and application thereof Download PDFInfo
- Publication number
- CN110960502A CN110960502A CN201811134717.XA CN201811134717A CN110960502A CN 110960502 A CN110960502 A CN 110960502A CN 201811134717 A CN201811134717 A CN 201811134717A CN 110960502 A CN110960502 A CN 110960502A
- Authority
- CN
- China
- Prior art keywords
- inulin
- seed oil
- embedded
- fructo
- oligosaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 30
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 30
- 239000000126 substance Substances 0.000 title claims abstract description 18
- 244000043261 Hevea brasiliensis Species 0.000 claims abstract description 78
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 78
- 229920001202 Inulin Polymers 0.000 claims abstract description 76
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 76
- 229940029339 inulin Drugs 0.000 claims abstract description 76
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 66
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 66
- 239000003094 microcapsule Substances 0.000 claims abstract description 61
- 239000003814 drug Substances 0.000 claims abstract description 24
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 235000013402 health food Nutrition 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims description 50
- 239000000843 powder Substances 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 239000006188 syrup Substances 0.000 claims description 11
- 235000020357 syrup Nutrition 0.000 claims description 11
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- 239000011162 core material Substances 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 238000004945 emulsification Methods 0.000 claims description 8
- 238000005516 engineering process Methods 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 239000004519 grease Substances 0.000 claims description 8
- 238000000265 homogenisation Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims description 8
- 235000020183 skimmed milk Nutrition 0.000 claims description 8
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 8
- 235000019982 sodium hexametaphosphate Nutrition 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 2
- YZNWXXJZEDHRKB-UHFFFAOYSA-N octadecyl 2-hydroxypropanoate;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCCOC(=O)C(C)O YZNWXXJZEDHRKB-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 5
- 230000003203 everyday effect Effects 0.000 abstract description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 26
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 19
- 241000700159 Rattus Species 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000007902 hard capsule Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 229960004586 rosiglitazone Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 108010010803 Gelatin Proteins 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 239000008273 gelatin Substances 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- 235000011852 gelatine desserts Nutrition 0.000 description 8
- 239000003292 glue Substances 0.000 description 7
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 6
- -1 fatty acid ester Chemical class 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229940080352 sodium stearoyl lactylate Drugs 0.000 description 6
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 description 6
- 229940116269 uric acid Drugs 0.000 description 6
- 208000004930 Fatty Liver Diseases 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- 230000035488 systolic blood pressure Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 2
- 108091005995 glycated hemoglobin Proteins 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000020124 milk-based beverage Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002352 surface water Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a substance for treating metabolic syndrome and application thereof. The substance is inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule, can be applied to medicine, health food, and can be used for treating and recovering metabolic syndrome patients. The metabolic syndrome patients can obtain good treatment and rehabilitation effects by directly taking or eating the medicine, health food and food added with the substance every day.
Description
Technical Field
The invention belongs to the field of biological medicines, and particularly relates to a substance (inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule) for treating metabolic syndrome and application thereof.
Background
The metabolic syndrome refers to a pathological state of metabolic disorder of substances such as protein, fat, carbohydrate and the like in a human body, is a complex metabolic disorder syndrome, and is a risk factor for causing diabetic cardiovascular and cerebrovascular diseases. Metabolic syndrome is a collection of various metabolic disorders including obesity, hyperglycemia, hypertension, dyslipidemia, high blood viscosity, hyperuricemia, high fatty liver incidence, and hyperinsulinemia; it can cause an increase in a number of diseases such as hypertension, coronary heart disease, stroke, and even certain cancers including sex hormone-related breast, endometrial, and prostate cancers, as well as pancreatic, liver and gall bladder, and colon cancers of the digestive system.
The metabolic syndrome seriously harms the health of people, but at present, no good solution exists in medicine. The existing medicines and treatment methods are basically limited to the stages of symptomatic treatment by special medicines aiming at different symptoms, such as blood pressure lowering medicines, blood sugar lowering medicines, blood fat lowering medicines and the like, and medicines and methods for integrally and comprehensively treating metabolic syndrome are lacked.
Disclosure of Invention
The invention aims to provide a substance (inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule) for treating and recovering metabolic syndrome patients, which is not available in the prior art, and an application thereof in pharmacy. The substance is inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule, can be directly eaten or applied to medicines, health foods and foods, and is used for treating and recovering metabolic syndrome patients. The metabolic syndrome patients can obtain good treatment and rehabilitation effects by directly taking or eating the medicine, health food and food added with the substance every day.
In order to achieve the above purpose of the present invention, the present invention provides the following technical solutions:
the main components are rubber tree seed oil and inulin or fructo-oligosaccharide; and embedding the rubber tree seed oil into a microcapsule form by adopting a micro-embedding technology and taking inulin or fructo-oligosaccharide as a wall material. The preparation method is technically characterized by comprising the following steps:
the composition comprises the following components in parts by weight: (1) core material grease: rubber tree seed oil (10-70% of dry weight of material); (2) wall material: inulin or fructo-oligosaccharide (type 75 syrup or 95% content powder) accounts for 20-85% of dry weight of the material; skimmed milk powder (0.03-0.08%); (3) and (3) the rest auxiliary materials: glucose syrup, which accounts for 5-10% of dry weight, mono-or di-glycerin fatty acid ester, sodium stearyl lactate, sodium hexametaphosphate, natural vitamin E and silicon dioxide. The production process comprises the steps of mixing → emulsification → homogenization → spray drying → finished powder.
The invention also provides a pharmaceutical composition containing the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule with a therapeutically effective amount and a pharmaceutically acceptable carrier.
And the health food consists of the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule and a common carrier of the health food.
And food, which consists of the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule and a common food carrier.
The invention also provides application of the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule in preparing a medicament for treating or recovering metabolic syndrome.
Use as described, wherein inulin or fructooligosaccharide embedded hevea brasiliensis seed oil microcapsules are used as the sole active ingredient.
The invention also provides application of the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule in preparing health-care food for treating or recovering metabolic syndrome.
And the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule is applied to preparing the food for rehabilitating metabolic syndrome.
Use as described, wherein inulin or fructooligosaccharide embedded hevea brasiliensis seed oil microcapsules are used as the sole active ingredient.
According to the experimental data of the animal model of the metabolic syndrome and other experimental data, compared with the existing medicine for treating and recovering a specific disease of a patient with the metabolic syndrome, the medicine has the following advantages that:
1. provides a brand new substance for the treatment and rehabilitation of patients with metabolic syndrome;
2. has no side effect, and can be used for long term for patients with metabolic syndrome.
Detailed Description
The following examples are provided to further illustrate the essence of the present invention, but are not intended to limit the present invention.
Example 1
A substance for treating and recovering metabolic syndrome patients is characterized in that the main components are rubber tree seed oil and inulin or fructo-oligosaccharide; and embedding the rubber tree seed oil into a microcapsule form by adopting a micro-embedding technology and taking inulin or fructo-oligosaccharide as a wall material. The preparation method is technically characterized by comprising the following steps: the composition comprises the following components in parts by weight: (1) core material grease: rubber tree seed oil (70% of dry weight material); (2) wall material: inulin (95% content powder) accounted for 25% of dry weight of the material; skimmed milk powder (0.05%); (3) and (3) the rest auxiliary materials: glucose syrup, which accounts for 5 percent of dry weight of the materials, (mono-glycerol and di-glycerol) fatty acid ester, sodium stearoyl lactylate, sodium hexametaphosphate, natural vitamin E and silicon dioxide. The production process comprises the steps of burdening → emulsification → homogenization → spray drying → finished powder;
the 50 successfully molded rats are randomly divided into 5 groups, namely a model group, a high, medium and low formula group (wherein the high, medium and low are calculated by the addition amount of rubber tree seed oil) of inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsules and a rosiglitazone group. Each group of rats was gavaged at 9:00 am every day, and the model group and the normal group were gavaged with double distilled water; intragastrically administering rosiglitazone 3mg/kg rosiglitazone hydrochloride suspension (preparation of rosiglitazone hydrochloride suspension, taking 3 and 4 mg/tablet of rosiglitazone hydrochloride, grinding into powder, dissolving in 12ml double distilled water, diluting to 1mg/ml, and using at present); the upper, middle and lower 3 formula groups of the invention are gavaged with 500mg/kg mixed solution every day (mixed solution preparation: 25g (10 g per bag) of the finished powder prepared in the embodiment is weighed and dissolved in 500ml of double distilled water to be diluted to 50mg/ml, and the mixed solution is used as it is). Rats were weighed 1 time per week, blood specimens and animal tissues were collected 8 weeks after intervention, and the corresponding index measurements were performed. The results are as follows:
1. general conditions given to groups of rats before and after
During the whole feeding process, rats in all groups do not die, and rats in normal groups have good state, normal activity, normal diet, sensitive reaction, glossy fur, plump muscles, long granular excrement and normal urine volume. During the 8-week drug intervention period, along with the treatment time, compared with the model group, the symptoms of polydipsia and diuresis of rats in each group are relieved, the activity, the hair color and the like are improved, the padding replacement frequency is reduced, and the symptoms of the rats in the rosiglitazone group are improved more remarkably;
2. comparison of fasting plasma glucose (FBG) levels in rats of various groups
No difference in FBG between the pre-administration model group and each treatment group: (P>0.05), but all are obviously increased compared with the normal group (P<0.05); after 4 weeks of administration, the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule high or low 3 formula groups and rosiglitazone FBG were all reduced compared with the model group, but the difference was not statistically significant (P>0.05) and the FBG in each treatment group model group is reduced after 6 weeks of administration (P<0.05), week 8, the FBG reduction of inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule high dose formula group and rosiglitazone group was very significant compared to the model group (P<0.01), but the comparison between the two is not statistically significant (P>0.05);
3. Comparison of fasting serum insulin (FINS) and insulin resistance Steady State model assessment (HOMA-IR) in rats of various groups
After 8 weeks of drug intervention, the rats in each treatment group had a reduction in FINS and HOMA-IR (P) compared to the model group<0.05), the dosage formula group and the rosiglitazone group in the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule have obvious effects (P<0.01) but the difference is not statisticalMeans (P>0.05);
4. Change in Systolic Blood Pressure (SBP) in rats of each group
The difference of SBP between the pre-administration model and each treatment group has no statistical significance, but is obviously increased (P) compared with the normal group<0.05). After 6 weeks of administration, SBP of inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule low dose formulation group was reduced compared to model group, and the difference was statistically significant (P)<0.05). After 8 weeks of administration, SBP was decreased in each treatment group compared with the model group (P)<0.05), significant in the 3:1 formulation group (P<0.01). Inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule low dose formula group has statistical significance compared with rosiglitazone group (P<0.05);
5. Change in diastolic pressure (DBP) in rats in each group
The difference between DBP in the pre-administration model and each treatment group has no statistical significance, but is obviously increased compared with the normal group (P<0.05). After 8 weeks of administration, the DBP in each treatment group was decreased compared to that before administration, but the difference was not statistically significant (1)P>0.05);
6. Comparison of lipid metabolism levels in rats of each group
After 8 weeks of treatment, inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule high dose formula group showed statistically significant reductions in TG, TC and LDL-C, increases in HDL-C and differences compared to the model group (1P<0.05); the differences in TC for the inulin-or fructooligosaccharide-encapsulated hevea brasiliensis seed oil microcapsule high dose formulation group compared to the rosiglitazone group are statistically significant ((P<0.05)。
Example 2
A substance for treating and recovering metabolic syndrome patients is characterized in that the main components are rubber tree seed oil and inulin or fructo-oligosaccharide; and embedding the rubber tree seed oil into a microcapsule form by adopting a micro-embedding technology and taking inulin or fructo-oligosaccharide as a wall material. The preparation method is technically characterized by comprising the following steps:
the composition comprises the following components in parts by weight: (1) core material grease: rubber tree seed oil (70% of dry weight material); (2) wall material: inulin (95% content powder) accounted for 25% of dry weight of the material; skimmed milk powder (0.05%); (3) and (3) the rest auxiliary materials: glucose syrup, which accounts for 5 percent of dry weight of the materials, (mono-glycerol and di-glycerol) fatty acid ester, sodium stearoyl lactylate, sodium hexametaphosphate, natural vitamin E and silicon dioxide. The production process comprises the steps of burdening → emulsification → homogenization → spray drying → finished powder;
mr. chen, 36 years old, ancestral nationality Shaanxi Ankang, works in all the adults, weighs 70 kilograms when young people enter, moves less after the people retreat, and needs more work to compensate, the weight reaches 95 kilograms, the body weight index is 31.3, mr. chen is found to be high before 2 years, 1 month in 2018 goes to a hospital for physical examination, triglyceride is 12.42mmol/L, the normal upper limit of triglyceride is 1.7mmol/L, the index of mr. chen is 7.3 times of the normal upper limit, and the index is very dangerous blood fat level;
by introduction of friends, mr. chen knows that the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule prepared in the embodiment is eaten after physical examination in 1 month, 15g (warm boiled water is taken) each time, twice a day, and 2 months continuously, namely 3 months in this year, mr. chen also goes to the same hospital for physical examination, triglyceride is reduced to 3.93mmol/L from 12.42mmol/L, foot is reduced by 70%, and is reduced to one third of original value, although the number is higher, the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule is no longer a terrorist number.
Example 3
A substance for treating and recovering metabolic syndrome patients is characterized in that the main components are rubber tree seed oil and inulin or fructo-oligosaccharide; and embedding the rubber tree seed oil into a microcapsule form by adopting a micro-embedding technology and taking inulin or fructo-oligosaccharide as a wall material. The preparation method is technically characterized by comprising the following steps:
the composition comprises the following components in parts by weight: (1) core material grease: rubber tree seed oil (60% of dry weight material); (2) wall material: inulin (95% content powder) accounted for 30% of the dry weight of the material; skimmed milk powder (0.05%); (3) and (3) the rest auxiliary materials: glucose syrup, which accounts for 10 percent of dry weight of the materials, (mono-glycerol and di-glycerol) fatty acid ester, sodium stearoyl lactylate, sodium hexametaphosphate, natural vitamin E and silicon dioxide. The production process comprises the steps of burdening → emulsification → homogenization → spray drying → finished powder;
mr. Shen, living in Yunnan Red river, age 46, has familial diabetes, high blood sugar, and high blood sugar value in 8 months physical examination in 2017, and is not qualified in various indexes; physical examination report of 8 months in 2017: fructosamine: 2.75 mmol/L; glycated hemoglobin: 11.6 percent; blood sugar 12.55 mmol/L;
when the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule prepared by the embodiment is continuously eaten for 4 months in the present year, 10g (warm boiled water is taken) is eaten before each meal, three times a day, and the patient goes to a hospital for secondary physical examination in 7 months in the present year, so that diabetes is improved a lot, and blood sugar is obviously reduced; examination report of 7 months in 2018: fructosamine: 1.52 mmol/L; glycated hemoglobin: 9.06 percent; glucose: 7.97 mmol/L.
Example 4
A substance for treating and recovering metabolic syndrome patients is characterized in that the main components are rubber tree seed oil and inulin or fructo-oligosaccharide; and embedding the rubber tree seed oil into a microcapsule form by adopting a micro-embedding technology and taking inulin or fructo-oligosaccharide as a wall material. The preparation method is technically characterized by comprising the following steps:
the composition comprises the following components in parts by weight: (1) core material grease: rubber tree seed oil (50% of dry weight material); (2) wall material: inulin (95% content powder) accounted for 40% of the dry weight of the material; skimmed milk powder (0.05%); (3) and (3) the rest auxiliary materials: glucose syrup, which accounts for 10 percent of dry weight of the materials, (mono-glycerol and di-glycerol) fatty acid ester, sodium stearoyl lactylate, sodium hexametaphosphate, natural vitamin E and silicon dioxide. The production process comprises the steps of burdening → emulsification → homogenization → spray drying → finished powder;
mr. Wang, living in Yunnan Red river, age 46, not only has familial diabetes, but also has high uric acid. The uric acid value in the physical examination report of 8 months in 2017 is 433 [ mu ] mol/L, the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule prepared in the embodiment is contacted in the next half year in 2017, but the eating is intermittent and not serious at that time, and the index of body 'floating' is not regarded as a new thing, and 15g (warm boiled water) is eaten at home for 2 times a day after 2018. In 2018, 7 months, the patient goes to the hospital again to be checked, the blood sugar is reduced, and the uric acid value is 425 mu mol/L and is reduced to the normal range.
Example 5
A substance for treating and recovering metabolic syndrome patients is characterized in that the main components are rubber tree seed oil and inulin or fructo-oligosaccharide; and embedding the rubber tree seed oil into a microcapsule form by adopting a micro-embedding technology and taking inulin or fructo-oligosaccharide as a wall material. The preparation method is technically characterized by comprising the following steps:
the composition comprises the following components in parts by weight: (1) core material grease: rubber tree seed oil (40% of dry weight material); (2) wall material: inulin (95% content powder) accounted for 50% of the dry weight of the material; skimmed milk powder (0.08%); (3) and (3) the rest auxiliary materials: glucose syrup, which accounts for 10 percent of dry weight of the materials, (mono-glycerol and di-glycerol) fatty acid ester, sodium stearoyl lactylate, sodium hexametaphosphate, natural vitamin E and silicon dioxide. The production process comprises the steps of burdening → emulsification → homogenization → spray drying → finished powder;
zheng Mr. 80 later, living in Yunnan, and after walking into the early years, the weight continuously rises, the physical quality is gradually improved, the user is often accompanied, the user can not eat or drink the wine, and the person can not be as young as staying late in the morning or late in the evening. Eating outside frequently, the physical condition is worse and worse, and the patient is in physical examination in 2015 with mild fatty liver; 2016, with fatty liver;
in 2018, 1 month, Zheng Mr. determines to change the current situation, and determines to reduce the body fat rate of the patient to eliminate fatty liver. Zheng Xiansheng starts eating the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule prepared by the embodiment 15g (warm boiled water for oral administration) each time, 2 times a day, and the period is kept without interruption. In 2018, in 3 months, the company organizes the workers to check, all indexes of Zheng Mr. are normal, and the fatty liver is not existed. After the physical indexes are good, the immunity is also good, and the cold is rarely caused.
Example 6
A substance for treating and recovering metabolic syndrome patients is characterized in that the main components are rubber tree seed oil and inulin or fructo-oligosaccharide; and embedding the rubber tree seed oil into a microcapsule form by adopting a micro-embedding technology and taking inulin or fructo-oligosaccharide as a wall material. The preparation method is technically characterized by comprising the following steps:
the composition comprises the following components in parts by weight: (1) core material grease: rubber tree seed oil (60% of dry weight material); (2) wall material: fructo-oligosaccharide (type 75 syrup) accounts for 30% of dry weight of the material; skimmed milk powder (0.08%); (3) and (3) the rest auxiliary materials: glucose syrup, which accounts for 10 percent of dry weight of the materials, (mono-glycerol and di-glycerol) fatty acid ester, sodium stearoyl lactylate, sodium hexametaphosphate, natural vitamin E and silicon dioxide. The production process comprises the steps of burdening → emulsification → homogenization → spray drying → finished powder;
mr. Cao, Shanxi, aged 55 years this year, had suffered from hypertension for more than twenty years, examined hyperglycemia and hyperlipidemia in 6 months in 2018, blood glucose value was 7.5mmol/L, blood lipid was 2.47mmol/L, uric acid was out of the normal range, uric acid value was 365.2. mu. mol/L, these let Mr. Cao find their own health problems more and more serious. The hypotensive drugs are taken before physical examination, and some people are not willing to take more drugs after the hyperglycemia and the hyperlipidemia are detected. Listening friends introduce the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule prepared by the embodiment, people can start to taste and eat by themselves, 15g (taking with boiled water) is eaten before each meal, 2 times a day is eaten, and after two months, physical examination is carried out again in 8 months in 2018, so that not only is uric acid reduced, blood sugar reduced to 6.84mmol/L from 7.5mmol/L, blood pressure reduced to 130/103Hg from 160/110Hg before, and blood fat reduced to 1.04mmol/L from 2.47 mmol/L.
Example 7
Inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsules of the invention, prepared as in examples 2-6, can be used directly as a powder. The powder can be used as medicine, health food or food.
Example 8
Inulin or fructo-oligosaccharide-embedded hevea brasiliensis seed oil microcapsules of the present invention were prepared as in examples 2-6, and excipients were added in a ratio of 1:1 or 1:2 by weight of the fraction to excipients, and granulated and tabletted. The tablet can be used as medicine, health food or food.
Example 9
The inulin or fructo-oligosaccharide-embedded rubber tree seed oil microcapsules of the present invention were prepared in the same manner as in examples 2 to 6, and according to the portions, they were wrapped in the hard capsule wall material to prepare hard capsules by a conventional hard capsule preparation method. The hard capsule can be used as medicine, health food or food.
Example 10
Inulin or fructo-oligosaccharide embedded hevea brasiliensis seed oil microcapsules of the present invention were prepared as in examples 2-6, and then tableted as follows:
inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule 100mg
Proper amount of starch
Proper amount of corn steep liquor
Proper amount of magnesium stearate
The preparation method comprises the following steps: mixing inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule with adjuvant, sieving, mixing in suitable container, granulating, and tabletting.
Example 11
Inulin or fructo-oligosaccharide embedded hevea brasiliensis seed oil microcapsules of the present invention were prepared as in examples 2-6, and hard capsules were prepared from this fraction as follows:
inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule 1000mg
Appropriate amount of gelatin
Proper amount of glycerin
Proper amount of water
The preparation method comprises the following steps: soaking gelatin and glycerol in distilled water to make gelatin swell and soften, and stirring and mixing to obtain capsule wall material gelatin solution. Taking out the prepared capsule material glue solution, coating the glue solution in a hard capsule grinding tool to ensure that the thickness is uniform, and then heating the glue solution at the temperature of about 90 ℃ to evaporate the surface water to obtain the hard capsule tablet with certain toughness and certain elasticity. Finally, inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsules (500 mg) are filled into hard capsule tablets to produce hard capsules.
Example 12
And (3) tablet preparation: inulin or fructo-oligosaccharide-embedded rubber tree seed oil microcapsules of the present invention were prepared in the same manner as in examples 2-6, containing 10mg of inulin or fructo-oligosaccharide, 180mg of lactose, 55mg of starch, and 5mg of magnesium stearate;
the preparation method comprises the following steps: inulin or fructo-oligosaccharide-embedded rubber tree seed oil microcapsules of the invention obtained as described in examples 2 to 6, lactose and starch were mixed, uniformly moistened with water, the moistened mixture was sieved and dried, sieved again, magnesium stearate was added, and the mixture was tabletted to a weight of 250mg per tablet, the content of inulin or fructo-oligosaccharide-embedded rubber tree seed oil microcapsules of the invention being 10 mg.
Example 13
And (3) capsule preparation: 2000g of inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule, 1000g of gelatin, 500g of glycerol, 1000g of water according to the present invention were prepared as in examples 2 to 6;
the preparation method comprises the following steps: 1000g of gelatin and 500g of glycerol are put into 1000g of water to be soaked so as to swell and soften the gelatin, and then the gelatin and the glycerol are stirred and mixed uniformly to obtain capsule wall glue solution. Taking out the prepared capsule material glue solution, coating the glue solution in a hard capsule grinding tool to ensure that the thickness is uniform, and then heating the glue solution at the temperature of about 90 ℃ to evaporate the surface water to obtain the hard capsule tablet with certain toughness and certain elasticity. And finally, filling 500mg of inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsules into hard capsule tablets to produce hard capsules. Each soft capsule weighs 750mg, and the content of the inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsule is 500 mg.
Example 14
Food and health food: inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsules of the present invention were prepared as described in examples 2-6 and were taken directly as a powder with hot water.
The preparation method comprises the following steps: 10g of inulin or fructo-oligosaccharide embedded hevea brasiliensis seed oil microcapsules of the present invention prepared as in examples 2-6 were added to 120ml of hot water at a temperature of 40-100 ℃ and melted to obtain a cup of milk-based drink. In the cup milk beverage, the content of inulin or fructo-oligosaccharide embedded rubber tree seed oil microcapsules is 10 g.
The foregoing is a more detailed description of the invention that is presented in conjunction with specific embodiments, and the practice of the invention is not to be considered limited to those descriptions. For those skilled in the art to which the invention pertains, several simple deductions or substitutions can be made without departing from the spirit of the invention, and all shall be considered as belonging to the protection scope of the invention.
Claims (10)
1. A substance for treating and recovering metabolic syndrome patients is characterized in that the main components are rubber tree seed oil and inulin or fructo-oligosaccharide; embedding rubber tree seed oil into a microcapsule form by adopting a micro-embedding technology and taking inulin or fructo-oligosaccharide as a wall material; the preparation method is technically characterized by comprising the following steps:
the composition comprises the following components in parts by weight: (1) core material grease: rubber tree seed oil (10-70% of dry weight of material); (2) wall material: inulin or fructo-oligosaccharide (type 75 syrup or 95% content powder) accounts for 20-85% of dry weight of the material; skimmed milk powder (0.03-0.08%); (3) and (3) the rest auxiliary materials: glucose syrup, which accounts for 5-10% of dry weight, mono-or di-glycerin fatty acid ester, sodium stearyl lactate, sodium hexametaphosphate, natural vitamin E and silicon dioxide;
the production process comprises the steps of mixing → emulsification → homogenization → spray drying → finished powder.
2. A pharmaceutical composition comprising a therapeutically effective amount of inulin or fructooligosaccharide embedded hevea brasiliensis seed oil microcapsules of claim 1 and a pharmaceutically acceptable carrier.
3. A health food comprising inulin or fructooligosaccharide-embedded rubber tree seed oil microcapsules of claim 1 and a carrier conventionally used in health foods.
4. A food product consisting of inulin or fructooligosaccharide embedded hevea brasiliensis seed oil microcapsules of claim 1 and a food product common carrier.
5. Use of inulin or fructooligosaccharide embedded hevea brasiliensis seed oil microcapsules according to claim 1 for the preparation of a medicament for the treatment or rehabilitation of metabolic syndrome.
6. Use according to claim 5, wherein inulin or fructooligosaccharide embedded hevea brasiliensis seed oil microcapsules are used as the sole active ingredient in a medicament.
7. Use of inulin or fructooligosaccharide embedded hevea brasiliensis seed oil microcapsules according to claim 1 for the preparation of a health food for the treatment or rehabilitation of metabolic syndrome.
8. Use according to claim 7, wherein inulin or fructooligosaccharide embedded hevea brasiliensis seed oil microcapsules are used as the sole active ingredient.
9. Use of inulin or fructooligosaccharide embedded hevea brasiliensis seed oil microcapsules according to claim 1 for the preparation of a foodstuff for rehabilitating metabolic syndrome.
10. The use according to claim 9, wherein inulin or fructooligosaccharide embedded hevea brasiliensis seed oil microcapsules are used as the sole active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811134717.XA CN110960502A (en) | 2018-09-28 | 2018-09-28 | Substance for treating metabolic syndrome and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811134717.XA CN110960502A (en) | 2018-09-28 | 2018-09-28 | Substance for treating metabolic syndrome and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110960502A true CN110960502A (en) | 2020-04-07 |
Family
ID=70026669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811134717.XA Pending CN110960502A (en) | 2018-09-28 | 2018-09-28 | Substance for treating metabolic syndrome and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110960502A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109329942A (en) * | 2018-11-08 | 2019-02-15 | 安颖 | A kind of composition and preparation method thereof with adjusting intestinal flora function |
WO2023235938A1 (en) * | 2022-06-10 | 2023-12-14 | University Of South Australia | Compositions comprising lipid droplets encapsulated within polysaccharide walls and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105104584A (en) * | 2015-09-24 | 2015-12-02 | 菏泽尧舜牡丹生物科技有限公司 | Preparation method of peony seed powdered oil containing active peptides |
CN107712543A (en) * | 2017-09-20 | 2018-02-23 | 徐宝军 | A kind of deflocculation curcumin microcapsule, preparation method and applications |
-
2018
- 2018-09-28 CN CN201811134717.XA patent/CN110960502A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105104584A (en) * | 2015-09-24 | 2015-12-02 | 菏泽尧舜牡丹生物科技有限公司 | Preparation method of peony seed powdered oil containing active peptides |
CN107712543A (en) * | 2017-09-20 | 2018-02-23 | 徐宝军 | A kind of deflocculation curcumin microcapsule, preparation method and applications |
Non-Patent Citations (5)
Title |
---|
CARLISE B. FRITZEN-FREIRE 等: "Effect of microencapsulation on survival of Bifidobacterium BB-12 exposed to simulated gastrointestinal conditions and heat treatments", 《LWT - FOOD SCIENCE AND TECHNOLOGY》 * |
PEDRO HENRIQUE CAMPELO-FELIX 等: "Prebiotic Carbohydrates: Effect on Reconstitution, Storage, Release, and Antioxidant Properties of Lime Essential Oil Microparticles", 《JOURNAL OF AGRICULTURAL & FOOD CHEMISTRY》 * |
何美莹 等: "关于云南橡胶种子油食用开发现与思考", 《热带农业科技》 * |
吴克刚,柴向华编著: "《食品微胶囊技术》", 31 July 2006, 中国轻工业出版社 * |
曹劲松,王晓琴编著: "《食品营养强化剂》", 31 January 2002, 中国轻工业出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109329942A (en) * | 2018-11-08 | 2019-02-15 | 安颖 | A kind of composition and preparation method thereof with adjusting intestinal flora function |
WO2023235938A1 (en) * | 2022-06-10 | 2023-12-14 | University Of South Australia | Compositions comprising lipid droplets encapsulated within polysaccharide walls and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101940620B (en) | Medicinal composition for treating diabetes mellitus and application thereof | |
CN102018832B (en) | Weight-reducing composition and preparation method thereof | |
CN110960502A (en) | Substance for treating metabolic syndrome and application thereof | |
WO2018077275A1 (en) | Composition for protecting eyesight and preparation method therefor | |
CN102872062A (en) | Medicinal composition for treating or preventing obesity and metabolic syndromes | |
US11623010B2 (en) | Pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition and methods for treatment | |
EP2635130A1 (en) | Composition of purified soluble mannans for dietary supplements and methods of use thereof | |
CN111281902A (en) | Application of lithocarpus litseifolius or active extract thereof | |
CN101543297A (en) | Oat beta-glucan hypolipemic capsule and a preparing method thereof | |
WO2014134833A1 (en) | Edible composition, preparation method therefor, and food product comprising the composition | |
KR20230145464A (en) | Drug composition for treating hyperlipidemia and method for producing the same | |
CN104840480B (en) | Metformin/folic acid/vitamin B12New application of pharmaceutical composition | |
CN109793780A (en) | It is a kind of for the hypoglycemic substance of type II diabetes, preparation method and applications | |
CN105920017B (en) | A kind of medical composition and its use for treating simple obesity | |
US11744870B2 (en) | Traditional Chinese medicine composition for treating metabolic syndrome and preparations thereof | |
CN108245625A (en) | A kind of hypoglycemic composition and preparation method thereof and purposes | |
CN103877533B (en) | Pharmaceutical composition of a kind for the treatment of diabetes containing metformin and preparation method thereof | |
CN110585358B (en) | Application of sorghum bran total flavonoids in preventing and treating gout diseases | |
CN110404029B (en) | Composition with blood sugar reducing effect and preparation method and application thereof | |
CN109793778A (en) | A kind of substance of blood pressure lowering, preparation method and applications | |
CN108261511A (en) | A kind of composition with antiobesity action and preparation method thereof and purposes | |
WO2021111980A1 (en) | Prophylactic or ameliorating agent for orthostatic hypotension, and composition containing same | |
CN110960568A (en) | Substance for improving intestinal microorganisms of human body and application thereof | |
CN109793790A (en) | A kind of substance of blood pressure lowering, using and preparation method thereof | |
CN112807392A (en) | Traditional Chinese medicine composition for pre-diabetic population and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |